Profiling bronchoalveolar fluid in a comparison between mild or critical COVID-19 patients revealed not only numeric differences in T-cells exhibiting good effector function, but also a discriminatory lower activity of anti-viral type 1 and II IFN signalling pathways in critical COVID-19 cases. This evidence concerns the gene IFNA1 and COVID-19.